Vous êtes sur la page 1sur 1

ANTIHYPERTENSION

ACE INHIBITORS
- are suitable for initiation and maintenance of therapy
- 1st line treatment for patient <55yr
- Have been shown to reduce mortality and morbidity in patients with CHF and
post MI
Action : block the conversion of angiotensin I to angiotension II by inhibiting ACE
Effect : lower BP by vasodilatation and reduction of peripheral resistance
- produce reduction in preload and afterload in patients with HF and they reduce
left ventricular remodeling which is a process that often follows MI
- generally well-tolerated and not effect lipid or glucose metabolism
Preparates : benazepril, captopril, cilazapril, delapril, enalapril, fosinopril,
imidapril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril

ALPHA-BLOCKERS
- usually preferred antihypertensive in patients with BPH
- there is limited evidence favoring use of alpha-blockers compared to the evidence
for other antihypertensive agents
Actions : lower BP by reducing peripheral resistance
- they also reduce prostatic and urethral smooth muscle tone
- provides symptomatic relief for patients with early BPH
- favorable effect on lipid metabolism
Preparates : bunazosin, doxazosin, prazosin, terazosin

ANGIOTENSIN II ANTAGONISTS
- are suitable for initiation and maintenance of therapy
- 1st line of therapy for patients <55 yr with contraindication for ACE inhibitors
- Beneficial effect in early and advanced type 2 DM nephropathy
- Should be considered in HF patients intolerant of ACE inhibitors
Actions : block type I angiotensin II receptors